BrainStorm Cell Therapeutics ran into another stumbling block with ALS hopeful NurOwn Thursday as the FDA issued a Refusal to File Letter for its Biologics License Application.
https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceFDAlogo4-25-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-10 10:18:322022-11-10 12:17:48BrainStorm denied again in ALS as FDA issues Refuse-to-File Letter
